CD274 and non-small cell lung carcinoma: The molecular probes targeting PD-L1 can be categorized into 3 types based on their molecular structure: Firstly, antibody-based probes, such as [89Zr]Zr-nivolumab, are derived from full-length antibodies and are used to target PD-L1 expression, assessing intertumor and intratumor heterogeneity in conditions like NSCLC [23].